Coave Therapeutics–Fund+: investment, 202501 financing round Series A totalling €32m incl existing + co-investor Fund+ |
2025-01-09 |
Coave Therapeutics–SEVERAL: investment, 202501 financing round Series A €32m co-led by Novo Holdings + Bpifrance InnoBio |
2025-01-09 |
Numab–Cormorant Asset Management: investment, 202501 financing round Series C extension totalling CHF50m incl existing + co-lead investor Cormorant AM |
2025-01-09 |
Numab–SEVERAL: investment, 202501 financing round Series C extension CHF50m bringing total Series C to CHF180m |
2025-01-09 |
Alesta Therapeutics–Droia Ventures: investment, 202501 financing round Series A totalling €65m incl co-lead investor Droia Ventures |
2025-01-08 |
Alesta Therapeutics–Frazier: investment, 202501 financing round Series A totalling €65m incl co-lead investor Frazier Life Sciences |
2025-01-08 |
Alesta Therapeutics–Kendall Investor Relations: public relations, 202501 supply service existent by Kendall IR |
2025-01-08 |
Alesta Therapeutics–Novartis: investment, 202501 financing round Series A totalling €65m incl co-investor Novartis Venture Fund |
2025-01-08 |
Alesta Therapeutics–RTW Investments: investment, 202501 financing round Series A totalling €65m incl co-investor RTW Investments |
2025-01-08 |
Alesta Therapeutics–SEVERAL: investment, 202501 financing round Series A €65m co-led by Frazier Life Sciences + Droia Ventures |
2025-01-08 |
Alesta Therapeutics–SSI Strategy: investment, 202501 financing round Series A totalling €65m incl co-investor SSI Strategy |
2025-01-08 |
Alesta Therapeutics–Thuja Capital: investment, 202501 financing round Series A totalling €65m incl existing + co-investor Thuja Capital |
2025-01-08 |
Alesta Therapeutics–Vetter: investment, 202501 financing round Series A totalling €65m incl co-investor RV Invest |
2025-01-08 |
Orbis Medicines–Forbion: investment, 202501 financing round Series totalling €90m incl existing + co-investor Forbion |
2025-01-06 |
Orbis Medicines–SEVERAL: investment, 202501 financing round Series €90m led by NEA |
2025-01-06 |
HUB Organoids–Merck (DE): investment, 202412– acquisition €na of HUB Organoids Holding BV by Merck SIGNED |
2024-12-17 |
Formo Bio–EU (govt): credit, 202412– venture debt loan €35m from EIB |
2024-12-16 |
Mainz Biomed–SEVERAL: investment, 202412 follow-on offering $8m with 1.37m units (1 share + 1 Class A + 1 Class B warrant) at $5.85/unit |
2024-12-16 |
Tromp Medical–Gilde Investment: investment, 202412 investment by new investor Gilde Healthcare |
2024-12-16 |
VectorY–Vigo Consulting: public relations, 202412 service existent by Vigo Consulting |
2024-12-16 |
Abliva–Pharming: investment, 202412– acquisition cash tender offer SEK725m ($66.1m) at SEK 0.45/share by Pharming ANNOUNCED |
2024-12-15 |
RhyGaze–BioGeneration Ventures: investment, 202412 financing round Series A totalling $86m incl existing + co-investor BGV |
2024-12-13 |
RhyGaze–SEVERAL: investment, 202412 financing round Series A $86m led by GV |
2024-12-13 |
Andera Partners–New York Life: investment, 202412– acquisition €na of 40% minority share in Andera by New York Life Investments |
2024-12-12 |
Citryll–SEVERAL: investment, 202412 financing round Series B €85m co-led by JnJ JJDC + Forbion + Novartis Venture Fund |
2024-12-09 |
GSK–Muna Therapeutics: drug target discovery, 202412– collab strategic alliance €33.5m upfront + milestones MiND-MAP platform for Alzheimer targets |
2024-12-05 |
HexagonFab–Merck (DE): investment, 202412 financing round Series A totalling £6.6m of Abselion incl lead investor M Ventures |
2024-12-04 |
HexagonFab–SEVERAL: investment, 202412 financing round Series A £6.6m of Abselion led by M Ventures |
2024-12-04 |
miDiagnostics–Alychlo: investment, 202412 financing round Series D totalling €30m incl existing + co-investor Alychlo |
2024-12-04 |
miDiagnostics–Pamica: investment, 202412 financing round Series D totalling €30m incl existing + co-investor Pamica |
2024-12-04 |
miDiagnostics–SEVERAL: investment, 202412 financing round Series D €30m led by Thermo Fisher Scientific |
2024-12-04 |
miDiagnostics–Thermo Fisher: investment, 202412 financing round Series D totalling €30m incl lead investor Thermo Fisher Scientific |
2024-12-04 |
miDiagnostics–VMF Invest: investment, 202412 financing round Series D totalling €30m incl existing + co-investor VMF Invest |
2024-12-04 |
Carl Roth–Bio Inx: bioinks, 202411– distribution ww of entire portfolio of bioinks of Bio Inx by Carl Roth |
2024-11-27 |
Adcendo–SEVERAL: investment, 202411 financing round Series B $135m led by TCGX |
2024-11-26 |
Cradle Bio–Index Ventures: investment, 202411 financing round Series B totalling $73m incl existing + co-investor Index Ventures |
2024-11-26 |
Cradle Bio–Institutional Venture Partners: investment, 202411 financing round Series B totalling $73m incl new + lead investor IVP |
2024-11-26 |
Cradle Bio–Kindred Capital: investment, 202411 financing round Series B totalling $73m incl existing + co-investor Kindred Capital |
2024-11-26 |
Cradle Bio–SEVERAL: investment, 202411 financing round Series B $73m led by IVP |
2024-11-26 |
Grifols–Cradle Bio: protein engineering, 202411 supply existent Grifols is user of AI-based protein engineering platform |
2024-11-26 |
JnJ–Cradle Bio: protein engineering, 202411 supply existent JnJ Innovative Medicine is user of AI-based protein engineering platform |
2024-11-26 |
Novo Group–Cradle Bio: protein engineering, 202411 supply existent Novo Nordisk is user of AI-based protein engineering platform |
2024-11-26 |
Novonesis–Cradle Bio: protein engineering, 202411 supply existent Novonesis is user of AI-based protein engineering platform |
2024-11-26 |
Biotheus–BioNTech: investment, 202411– acquisition 100% for $800m upfront mostly in cash + few ADSs plus $150m milestones |
2024-11-13 |
Centogene–Charme Capital Partners: investment, 202411– acquisition €8.7m of sole operating subsidiary Centogene GmbH by affiliate of Charme Capital |
2024-11-13 |
Mainz Biomed–Thermo Fisher: colorectal cancer screening test, 202411– collab developm + commercialisation assays for mRNA-based CRC screening tests |
2024-11-12 |
Zymofix–High-Tech Gründerfonds: investment, 202411 financing round totalling €2m incl lead investor HTGF |
2024-11-12 |
Zymofix–SEVERAL: investment, 202411 financing round €2m led by HTGF |
2024-11-12 |
Kivu Bioscience–BioGeneration Ventures: investment, 202410 financing round Series A totalling $92m incl existing + co-investor BGV |
2024-10-28 |
Kivu Bioscience–Gimv: investment, 202410 financing round Series A totalling $92m incl new + co-investor Gimv |
2024-10-28 |
Kivu Bioscience–Lonza: ADC technology, 202410 existent use of GlycoConnect platform fo Synaffix by Kivu Bioscience |
2024-10-28 |
Kivu Bioscience–Merck (DE): investment, 202410 financing round Series A totalling $92m incl existing + co-investor M Ventures |
2024-10-28 |
Kivu Bioscience–Netherlands (govt): investment, 202410 financing round Series A totalling $92m incl existing + co-investor BOM |
2024-10-28 |
Kivu Bioscience–SEVERAL: investment, 202410 financing round Series A $92m led by Novo Holdings |
2024-10-28 |
Immatics–SEVERAL: investment, 202410– proposed public offering $150m |
2024-10-10 |
Lumicks–EU (govt): credit, 202410– venture debt financing €20m from EIB to advance high-througput cell avidity platform |
2024-10-10 |
Enara Bio–Merck (DE): investment, 202410 financing round Series B totalling $32.5m incl new + co-lead investor M Ventures |
2024-10-03 |
Enara Bio–SEVERAL: investment, 202410 financing round Series B $32.5m co-led by new investors Pfizer Ventures + M Ventures |
2024-10-03 |
LoQus23 Therapeutics–Forbion: investment, 202410 financing round Series A totalling £35m incl new + lead investor Forbion |
2024-10-02 |
LoQus23 Therapeutics–SEVERAL: investment, 202410 financing round Series A £35m led by new investor Forbion |
2024-10-02 |
LoQus23 Therapeutics–SV Health Investors: investment, 202410 financing round Series A totalling £35m incl existing + co-investor DDF |
2024-10-02 |
Roivant–Organon: investment, 202409– acquisition of Dermavant Sciences by Organon $175m upfront + $1.025b milestones plus royalties incl product Vtama |
2024-09-18 |
ImmunOs Therapeutics–Gimv: investment, 202409 financing round Series C totalling $11m incl existing + co-lead investor Gimv |
2024-09-17 |
ImmunOs Therapeutics–SEVERAL: investment, 202409 financing round Series C $11m led by Gimv + Pfizer Ventures + Mission BioCapital + BioMedPartners |
2024-09-17 |
Cell Signaling Technology–e-Blot Life Science: imaging system, 202409– distribution of Touch Imager system by Bioké in 12 European countries |
2024-09-16 |
Abolis Biotechnologies–Icos Capital: investment, 202409 financing round totalling €35m incl investor Icos Capital |
2024-09-12 |
Abolis Biotechnologies–SEVERAL: investment, 202409 financing round €35m with BOLD L’Oréal VC Fund + Evonik Venture Capital et al |
2024-09-12 |
Inflammatix–SEVERAL: investment, 202409 financing round Series E $57m led by Khosla Ventures + Think.Health |
2024-09-12 |
Inflammatix–Vesalius Biocapital: investment, 202409 financing round Series E totalling $57m incl co-investor Vesalius Biocapital |
2024-09-12 |
Novameat–Forbion: investment, 202409 financing round Series A totalling €17.4m incl new + co-lead investor Forbion BioEconomy Fund |
2024-09-12 |
Novameat–Praesidium: investment, 202409 financing round Series A totalling €17.4m incl existing + co-investor Praesidium |
2024-09-12 |
Novameat–Rubio Impact Ventures: investment, 202409 financing round Series A totalling €17.4m incl existing + co-investor Rubio Impact Ventures |
2024-09-12 |
Novameat–SEVERAL: investment, 202409 financing round Series A €17.4m led by Sofinnova Partners + Forbion BioEconomy Fund |
2024-09-12 |
Organon–Bao Pharmaceutical: long-acting FSH, 202409– license + supply agreem for SJ02 in Mainland China $12m upfront + milestones |
2024-09-12 |
PanTera–SEVERAL: investment, 202409 financing round Series A €93m led by EQT Life Sciences |
2024-09-11 |
Solasta Bio–SEVERAL: investment, 202409 financing round Series A $14m led by Forbion BioEconomy Fund |
2024-09-11 |
Formo Bio–SEVERAL: investment, 202409 financing round Series B $61m from existing + new investors |
2024-09-10 |
eGenesis–Lux Capital: investment, 202409 financing round Series D totalling $191m incl lead investor Lux Capital |
2024-09-04 |
eGenesis–SEVERAL: investment, 202409 financing round Series D $191m from existing + new investors led by Lux Capital |
2024-09-04 |
Mainz Biomed–Liquid Biosciences: AI-based cancer diagnostics, 202409– collab expansion using EMERGE platform to advance PancAlert screening test |
2024-09-04 |
Qiagen–SEVERAL: credit, 202409–2031 placement of $500m senior unsecured net share settled convertible bonds due 2031 |
2024-09-03 |
Caresyntax–SEVERAL: credit, 202408 up to $100m growth debt facility |
2024-08-15 |
Caresyntax–SEVERAL: investment, 202408 financing round Series C extension $80m |
2024-08-15 |
PL BioScience–Brightlands Venture Partners: investment, 202408 financing round Series A totalling €7.8m incl existing investor BVP Fund IV |
2024-08-08 |
PL BioScience–SEVERAL: investment, 202408 financing round Series A €7.8m with new + existing investors |
2024-08-08 |
PL BioScience–TechVision Fonds: investment, 202408 financing round Series A totalling €7.8m incl existing investor TechVision Fonds |
2024-08-08 |
NEC–Asahi Glass: contract manufacturing, 202408– collab developm production techn + supply cancer vaccine NECVAX-NEO1 by AGC Biologics + NEC Bio Tx |
2024-08-07 |
Confo Therapeutics–SEVERAL: investment, 202407 financing round Series B €60m led by Ackermans & van Haaren |
2024-07-26 |
Axa–Zyme Communications: public relations, 202406 service existent for Kadans Science Partner by Zyme |
2024-07-24 |
Draupnir Bio–ABP (NL): Investment, 202407 seed financing round totalling €12m incl existing investor Inkef Capital |
2024-07-17 |
Draupnir Bio–Gilde Investment: Investment, 202407 seed financing round totalling €12m incl existing investor Gilde Healthcare Partners |
2024-07-17 |
Draupnir Bio–SEVERAL: Investment, 202407 seed financing round €12m with MP Healthcare + EIFO + Gilde HP + Inkef Capital + Novo Holdings |
2024-07-17 |
Asceneuron–EQT: investment, 202407 financing round Series C totalling $100m incl new + co-investor EQT Life Sciences - LSP Dementia Fund |
2024-07-16 |
Asceneuron–Merck (DE): investment, 202407 financing round Series C totalling $100m incl existing + co-investor M Ventures |
2024-07-16 |
Asceneuron–OrbiMed: investment, 202407 financing round Series C totalling $100m incl new + co-investor OrbiMed |
2024-07-16 |
Asceneuron–SEVERAL: investment, 202407 financing round Series C $100m led by Novo Holdings |
2024-07-16 |
Catalym–Bioqube Ventures: investment, 202407 financing round Series D totalling $150m incl new + co-lead investor Bioqube Ventures |
2024-07-16 |
Catalym–Brandon Capital: investment, 202407 financing round Series D totalling $150m incl existing + co-investor Brandon Capital |
2024-07-16 |
Catalym–Canaan Partners: investment, 202407 financing round Series D totalling $150m incl new + co-lead investor Canaan Partners |
2024-07-16 |
Catalym–Forbion: investment, 202407 financing round Series D totalling $150m incl existing + co-investor Forbion Growth Opportunities Fund |
2024-07-16 |